Light-to-moderate dry eye disease (DED) represents the most common presentation in clinical ophthalmology. Patients typically report persistent ocular dryness, grittiness, and foreign-body sensation—symptoms that may temporarily improve with artificial tears but frequently recur due to unresolved underlying pathology. While lubricating drops provide symptomatic relief, they do not address the core driver of disease progression: chronic ocular surface inflammation. As a result, many patients seek more effective, mechanism-based therapies capable of delivering sustained symptom control.
Guidelines from the Chinese Expert Consensus on Clinical Diagnosis and Treatment of Dry Eye (2024) emphasize a stepwise, severity-adapted management strategy. For moderate DED—and increasingly for persistent or recurrent mild cases—the consensus recommends incorporating anti-inflammatory therapy alongside lubrication. This reflects a paradigm shift from purely palliative hydration toward targeted immunomodulation, recognizing that subclinical inflammation underlies tear film instability, goblet cell loss, and impaired lacrimal gland function—even in early-stage disease.
A key advancement in this therapeutic evolution is the introduction of low-concentration cyclosporine ophthalmic solution (0.05%), such as Zirun Cyclosporine Ophthalmic Solution (II). Supported by both national and international guidelines—including the 2026 Clinical Practice Guidelines for Dry Eye: A Comprehensive Approach—this formulation is now recognized as a first-line anti-inflammatory option for mild-to-moderate DED. Its 0.05% concentration delivers clinically meaningful immunomodulatory effects while maintaining an excellent safety profile, avoiding the risks of excessive immunosuppression associated with higher-dose regimens. The product’s labeling specifically indicates its use in patients with reduced tear production secondary to inflammation associated with keratoconjunctivitis sicca—a pathophysiological match for the majority of mild-to-moderate DED cases.
Early intervention with anti-inflammatory therapy offers significant clinical and economic advantages. Initiating treatment during the mild-to-moderate phase helps prevent structural damage—including corneal epithelial erosion, punctate keratopathy, and filamentary keratitis—that often necessitates complex multimodal regimens or even surgical interventions in advanced disease. In contrast, timely cyclosporine use supports restoration of lacrimal gland function and goblet cell density, promoting endogenous tear production and improving long-term ocular surface homeostasis. This makes the mild-to-moderate window a critical “golden period” for disease modification.
Zirun Cyclosporine Ophthalmic Solution (II) is therefore positioned not as a replacement for artificial tears, but as a complementary, disease-modifying agent. When used in combination—particularly during active symptom flares—it bridges the gap between symptomatic relief and pathophysiological correction. Clinical experience suggests that consistent use over approximately three months typically leads to measurable improvements in tear break-up time, Schirmer test values, and patient-reported outcomes. Following stabilization, clinicians may gradually taper artificial tear frequency while maintaining cyclosporine at a maintenance dose, ultimately optimizing therapeutic burden and long-term adherence.
Patient education remains integral to successful management. Individuals with mild-to-moderate DED are advised to adopt supportive lifestyle measures: limiting screen time with intentional blink retraining, ensuring adequate sleep hygiene, using humidifiers in air-conditioned environments, and scheduling comprehensive ocular surface evaluations—including tear film assessment—every three months to monitor treatment response and adjust therapy as needed.
Frequently Asked Questions:
How long should patients use cyclosporine for mild-to-moderate dry eye?
Most patients require continuous treatment for approximately 12 weeks to achieve stable symptom control and objective improvement in tear metrics. After this period, dosage reduction or discontinuation should be guided by clinical evaluation—not symptom absence alone.
Can cyclosporine be used without concurrent artificial tears?
During acute symptomatic phases, combination therapy is recommended. As inflammation subsides and tear production improves, artificial tear use can be systematically reduced under clinician supervision—aiming for minimal pharmacologic support while preserving ocular surface integrity.